WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO, NUROW) announced today that Synovation Medical Group will conduct an evaluation of Quell ® Wearable Pain Relief Technology™ in fibromyalgia patients. "We have seen both clinical data and positive reviews that suggest that Quell

WALTHAM, Mass. --(BUSINESS WIRE)--   NeuroMetrix, Inc.  (Nasdaq: NURO) announced today that Quell ® Wearable Pain Relief Technology ™ is available in Canada via Amazon Canada. "Canadian consumers have been asking for easier access to Quell," said Frank McGillin, SVP and General Manager of

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that WBC Group, LLC will be the exclusive distributor of Quell ® Wearable Pain Relief Technology ™ to chiropractors, physical therapists, physical fitness facilities and personal trainers through their MeyerDC,

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that Comprehensive Pain Specialists will offer Quell ® Wearable Pain Relief Technology™ in selected clinic locations. "We are pleased that a growing number of forward-thinking pain management providers are

WOBURN, Mass. , March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck ® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO, NUROW) announced today that it has promoted Frank McGillin to Senior Vice President and Chief Commercial Officer. Mr. McGillin's most recent title was Senior Vice President and GM Consumer. In the expanded role, Mr.

NeuroMetrix Announces Pricing of Securities Offering WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 8, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has priced a public offering of up to 10,500,000 Units at a price per Unit of $1.00 , for aggregate gross proceeds of up to $10,500,000 ,

WOBURN, Mass. , Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH -funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a

WOBURN, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research .

WOBURN, Mass. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner. C2SHIP is a U.S. National Science Foundation (NSF) funded consortium of leading academic centers and